Literature DB >> 8270035

Anaplastic carcinoma of the thyroid.

T Hadar1, C Mor, J Shvero, R Levy, K Segal.   

Abstract

A review of 48 cases of anaplastic cell carcinoma of the thyroid gland treated in the Department of E.N.T. of Beilinson Medical Center revealed more than 90% of the patients to be over 50 years of age. Twenty-five percent of the patients showed, histologically, areas of transition from differentiated carcinoma (either papillary or follicular) into anaplastic carcinoma. The patients were treated by surgery and/or irradiation and/or chemotherapy. Twenty-seven patients underwent subtotal or total thyroidectomy and 21 patients underwent biopsy or partial thyroidectomy. The survival rate was very poor, two-year survival rate was 28%. Twenty-eight of the patients (58%) died within one year of diagnosis.

Entities:  

Mesh:

Year:  1993        PMID: 8270035

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  18 in total

Review 1.  Anaplastic thyroid carcinoma.

Authors:  P I Haigh
Journal:  Curr Treat Options Oncol       Date:  2000-10

Review 2.  Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies.

Authors:  Eleonora Molinaro; Cristina Romei; Agnese Biagini; Elena Sabini; Laura Agate; Salvatore Mazzeo; Gabriele Materazzi; Stefano Sellari-Franceschini; Alessandro Ribechini; Liborio Torregrossa; Fulvio Basolo; Paolo Vitti; Rossella Elisei
Journal:  Nat Rev Endocrinol       Date:  2017-07-14       Impact factor: 43.330

3.  Deletions of the long arm of chromosome 10 in progression of follicular thyroid tumors.

Authors:  J Zedenius; G Wallin; A Svensson; J Bovèe; A Höög; M Bäckdahl; C Larsson
Journal:  Hum Genet       Date:  1996-03       Impact factor: 4.132

Review 4.  Anaplastic thyroid carcinoma: pathogenesis and emerging therapies.

Authors:  R C Smallridge; J A Copland
Journal:  Clin Oncol (R Coll Radiol)       Date:  2010-04-24       Impact factor: 4.126

5.  Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis.

Authors:  Roch-Philippe Charles; Jillian Silva; Gioia Iezza; Wayne A Phillips; Martin McMahon
Journal:  Mol Cancer Res       Date:  2014-04-25       Impact factor: 5.852

Review 6.  Surgical options in undifferentiated thyroid carcinoma.

Authors:  Brian Hung-Hin Lang; Chung-Yau Lo
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

Review 7.  Treatment of patients with anaplastic thyroid cancer during the last 20 years: whether any progress has been made?

Authors:  Vesna Bisof; Zoran Rakusic; Marija Despot
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-06-03       Impact factor: 2.503

8.  Prognostic factors of anaplastic thyroid carcinoma.

Authors:  J Y Jiang; F Y Tseng
Journal:  J Endocrinol Invest       Date:  2006-01       Impact factor: 4.256

9.  Efficacy of sorafenib and impact on cardiac function in patients with thyroid cancer: a retrospective analysis.

Authors:  L Mortara; G Pera; E Monti; S Morbelli; F Minuto; G Sambuceti; M Giusti
Journal:  J Endocrinol Invest       Date:  2014-10-05       Impact factor: 4.256

Review 10.  Anaplastic thyroid carcinoma: Updates on WHO classification, clinicopathological features and staging.

Authors:  Ichiro Abe; Alfred King-Yin Lam
Journal:  Histol Histopathol       Date:  2020-11-10       Impact factor: 2.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.